{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:41:21Z","timestamp":1738215681797,"version":"3.34.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We designed a questionnaire consisting of 34 items focused on physicans\u2019 clinical experiences with ICIs and their management of irAEs. The survey was distributed between October 2022 and May 2023 to medical professionals with experience in the field of gynecologic oncology.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 221 gynecologists participated in the study. Most respondents (<jats:italic>n<\/jats:italic>\u2009=\u2009130, 59.1%) were primarily engaged in gynecologic oncology at the time of the survey, with an average of ten years of clinical experience. Individual experiences with regard to irAEs varied significantly. When asked which irAEs they had observed \u201cfrequently\u201d or \u201cvery frequently\u201d, respondents most commonly reported thyroiditis (37.2%), followed by skin reactions (23.6%), and pneumonitis (10.6%). A total of <jats:italic>n<\/jats:italic>\u2009=\u200916 (7.4%) reported at least one death of a patient due to irAEs. Feeling \u201cunconfident\u201d or \u201cvery unconfident\u201d about managing irAEs was reported by 35.6% (<jats:italic>n<\/jats:italic>\u2009=\u200978). With regard to clinical management of adverse events after discontinuation of treatment, 32.4% (<jats:italic>n<\/jats:italic>\u2009=\u200968) ceased to inquire about irAEs after six months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The results of this survey provide valuable insights into physicians\u2019 real-world experiences with irAEs associated with ICI treatment. Dealing with serious immune-related and potentially life-threatening side effects has become a routine aspect of clinical practice. Many physicians, however, express a lack of sufficient familiarity with irAEs and their management. Therefore, it is essential to improve medical education, specialized oncological training, and close interdisciplinary collaboration to improve patient care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13432-5","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T08:25:11Z","timestamp":1738139111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO\/NOGGO survey"],"prefix":"10.1186","volume":"25","author":[{"given":"Maximilian","family":"Riedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bartl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Rossner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tatzber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Flethe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Zocholl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Schmalfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Pietzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"13432_CR1","doi-asserted-by":"publisher","unstructured":"Fontenot VE, Tewari K. The current status of immunotherapy in the treatment of primary advanced and recurrent endometrial cancer. Curr Opin Obstet Gynecol. 2023 Feb;35(1):34\u201342. https:\/\/doi.org\/10.1097\/GCO.0000000000000839","DOI":"10.1097\/GCO.0000000000000839"},{"key":"13432_CR2","doi-asserted-by":"publisher","first-page":"175883592311576","DOI":"10.1177\/17588359231157633","volume":"15","author":"AV Tinker","year":"2023","unstructured":"Tinker AV, et al. A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer. Ther Adv Med Oncol. 2023;15:17588359231157633. https:\/\/doi.org\/10.1177\/17588359231157633.","journal-title":"Ther Adv Med Oncol"},{"key":"13432_CR3","doi-asserted-by":"publisher","unstructured":"Schmidt MW, et al. Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of clinical trials. Cancers (Basel). Jan. 2022;14(2):441. https:\/\/doi.org\/10.3390\/cancers14020441.","DOI":"10.3390\/cancers14020441"},{"key":"13432_CR4","doi-asserted-by":"publisher","unstructured":"Schmid P et al. Feb., Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022 Feb;386(6):556\u2013567 https:\/\/doi.org\/10.1056\/NEJMoa2112651","DOI":"10.1056\/NEJMoa2112651"},{"key":"13432_CR5","doi-asserted-by":"publisher","unstructured":"Shiravand Y et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022 Apr;29(5):3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247","DOI":"10.3390\/curroncol29050247"},{"key":"13432_CR6","doi-asserted-by":"publisher","unstructured":"Geisler AN, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. Nov. 2020;83(5):1255\u201368. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132.","DOI":"10.1016\/j.jaad.2020.03.132"},{"key":"13432_CR7","doi-asserted-by":"publisher","unstructured":"Mizukoshi T, Fukuoka H, Takahashi Y. Immune checkpoint inhibitor-related hypophysitis. Best Pract Res Clin Endocrinol Metab. May 2022;36(3):101668. https:\/\/doi.org\/10.1016\/j.beem.2022.101668.","DOI":"10.1016\/j.beem.2022.101668"},{"issue":"11","key":"13432_CR8","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1159\/000509941","volume":"99","author":"G Gomatou","year":"2020","unstructured":"Gomatou G, Tzilas V, Kotteas E, Syrigos K, Bouros D. Immune Checkpoint inhibitor-related pneumonitis. Respiration. 2020;99(11):932\u201342. https:\/\/doi.org\/10.1159\/000509941.","journal-title":"Respiration"},{"key":"13432_CR9","doi-asserted-by":"publisher","unstructured":"Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Semin Cancer Biol. 2020 Aug;64:93\u2013101. https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.012","DOI":"10.1016\/j.semcancer.2019.06.012"},{"key":"13432_CR10","doi-asserted-by":"publisher","unstructured":"Ramos-Casals M, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. May 2020;6(1):38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6.","DOI":"10.1038\/s41572-020-0160-6"},{"key":"13432_CR11","doi-asserted-by":"publisher","unstructured":"Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E. Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs. 2020 Aug;34(4):463\u2013476. https:\/\/doi.org\/10.1007\/s40259-020-00425-y","DOI":"10.1007\/s40259-020-00425-y"},{"key":"13432_CR12","doi-asserted-by":"publisher","unstructured":"Giamello JD, Lauria G, Antonuzzo A, Bossi P, Lorenzati B, Numico G. A nationwide survey among emergency physicians and oncologists to improve the management of immune checkpoint inhibitors toxicity. Support Care Cancer. 2022 Aug;30(8):6365\u20136368.  https:\/\/doi.org\/10.1007\/s00520-022-06844-7","DOI":"10.1007\/s00520-022-06844-7"},{"key":"13432_CR13","doi-asserted-by":"publisher","unstructured":"Khalid AB, Calderon G, Jalal SI, Durm GA. Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. J Natl Compr Canc Netw. 2022 Dec;20(12):1316\u20131320. https:\/\/doi.org\/10.6004\/jnccn.2022.7064","DOI":"10.6004\/jnccn.2022.7064"},{"key":"13432_CR14","doi-asserted-by":"publisher","unstructured":"Nikendei C, Weyrich P, J\u00fcnger J, Schrauth M. Medical education in Germany. Med Teach. Jan. 2009;31(7):591\u2013600. https:\/\/doi.org\/10.1080\/01421590902833010.","DOI":"10.1080\/01421590902833010"},{"key":"13432_CR15","doi-asserted-by":"publisher","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. Apr. 2022;19(4):254\u201367. https:\/\/doi.org\/10.1038\/s41571-022-00600-w.","DOI":"10.1038\/s41571-022-00600-w"},{"key":"13432_CR16","doi-asserted-by":"publisher","unstructured":"Patrinely JR, et al. Chronic Immune-related adverse events following adjuvant Anti-PD-1 therapy for high-risk Resected Melanoma. JAMA Oncol. May 2021;7(5):744\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0051.","DOI":"10.1001\/jamaoncol.2021.0051"},{"key":"13432_CR17","doi-asserted-by":"publisher","unstructured":"Owen CN, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol. Jul. 2021;32(7):917\u201325. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.204.","DOI":"10.1016\/j.annonc.2021.03.204"},{"key":"13432_CR18","doi-asserted-by":"publisher","unstructured":"Schneider BJ et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec;39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","DOI":"10.1200\/JCO.21.01440"},{"key":"13432_CR19","doi-asserted-by":"publisher","unstructured":"Shehaj I, et al. Occurrence and management of Immunotherapy-Associated adverse events in patients with gynecological cancers. Cancers. Mar. 2024;16:1371. https:\/\/doi.org\/10.3390\/cancers16071371.","DOI":"10.3390\/cancers16071371"},{"key":"13432_CR20","doi-asserted-by":"publisher","unstructured":"Yin Q, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. May 2023;14:1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975.","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"13432_CR21","doi-asserted-by":"publisher","unstructured":"Wang DY et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec;4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"13432_CR22","doi-asserted-by":"publisher","unstructured":"Offner B, Rinke L. Immunotherapy Assessment: Using a Survey Instrument to Examine Oncology Nurses\u2019 Confidence Levels With Administration and Management. CJON. 2021 Jun;25(3):343\u2013346. https:\/\/doi.org\/10.1188\/21.CJON.343-346","DOI":"10.1188\/21.CJON.343-346"},{"key":"13432_CR23","unstructured":"ESMO - Clinical Practice Guideline \u2013 Management of Toxicities from Immunotherapy. Oct. 18. 2022. [Online]. Available: https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/esmo-clinical-practice-guidelines-supportive-and-palliative-care\/clinical-practice-guideline-management-of-toxicities-from-immunotherapy"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13432-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T08:25:16Z","timestamp":1738139116000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13432-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13432"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13432-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of Charit\u00e9-Universit\u00e4tsmedizin Berlin and registered under the license EA1\/198\/22. The study was conducted in accordance with the Declaration of Helsinki (version 2024). Participants provided electronic informed consent to participate and agreed electronically to data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}